Next FDA user fee deal is under review at the White Housenews2026-05-29T17:30:24+00:00May 29th, 2026|Endpoints News|
Post-Hoc: Lilly gets more secretive and hides Phase 1 pipelinenews2026-05-29T17:23:24+00:00May 29th, 2026|Endpoints News|
AstraZeneca seeks path for failed antibody; Imfinzi, Tremfya get label expansionsnews2026-05-29T15:30:30+00:00May 29th, 2026|Endpoints News|
Replimune will again submit its melanoma drug for approvalnews2026-05-29T15:07:17+00:00May 29th, 2026|Endpoints News|
Agios ends development of tebapivat in low-risk MDS following subpar resultsnews2026-05-29T14:50:57+00:00May 29th, 2026|Endpoints News|
#ASCO26: Bristol Myers details Phase 3 trial win for Pomalyst successornews2026-05-29T12:00:21+00:00May 29th, 2026|Endpoints News|
David Chang to hand over the reins at Allogene; Ex-Esperion CEO gets started at Phlownews2026-05-29T11:00:18+00:00May 29th, 2026|Endpoints News|
Pfizer strikes Innovent deal worth up to $10.5B for a dozen cancer programsnews2026-05-29T10:50:55+00:00May 29th, 2026|Endpoints News|
Lilly obesity meds Foundayo and Zepbound to gain CVS coveragenews2026-05-28T17:28:36+00:00May 28th, 2026|Endpoints News|
